Selected article for: "epidemiological evidence and mortality morbidity"

Author: Cheng, Paul; Zhu, Han; Witteles, Ronald M.; Wu, Joseph C; Quertermous, Thomas; Wu, Sean M.; Rhee, June-Wha
Title: Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty
  • Cord-id: lfjud2aq
  • Document date: 2020_4_29
  • ID: lfjud2aq
    Snippet: PURPOSE OF REVIEW: COronaVirus Disease 2019 (COVID-19) has spread at unprecedented speed and scale into a global pandemic with cardiovascular risk factors and complications emerging as important disease modifiers. We aim to review available clinical and biomedical literature on cardiovascular risks of COVID-19. RECENT FINDINGS: SARS-CoV2, the virus responsible for COVID-19, enters the cell via ACE2 expressed in select organs. Emerging epidemiological evidence suggest cardiovascular risk factors
    Document: PURPOSE OF REVIEW: COronaVirus Disease 2019 (COVID-19) has spread at unprecedented speed and scale into a global pandemic with cardiovascular risk factors and complications emerging as important disease modifiers. We aim to review available clinical and biomedical literature on cardiovascular risks of COVID-19. RECENT FINDINGS: SARS-CoV2, the virus responsible for COVID-19, enters the cell via ACE2 expressed in select organs. Emerging epidemiological evidence suggest cardiovascular risk factors are associated with increased disease severity and mortality in COVID-19 patients. Patients with a more severe form of COVID-19 are also more likely to develop cardiac complications such as myocardial injury and arrhythmia. The true incidence of and mechanism underlying these events remain elusive. SUMMARY: Cardiovascular diseases appear intricately linked with COVID-19, with cardiac complications contributing to the elevated morbidity/mortality of COVID-19. Robust epidemiologic and biologic studies are urgently needed to better understand the mechanism underlying these associations to develop better therapies.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and acute cardiac injury: 1, 2
    • ace inhibitor and acute lung injury: 1, 2, 3, 4
    • acei arb treatment and acute lung injury: 1
    • acei arb treatment and losartan treatment: 1
    • acute cardiac injury and additional study: 1
    • acute lung injury and additional study: 1
    • acute lung injury and longitudinal study: 1
    • acute lung injury and losartan treatment: 1
    • acute lung injury and low airway: 1
    • acute lung injury and lung compare: 1
    • additional study and longitudinal study: 1, 2, 3, 4, 5, 6, 7, 8
    • longitudinal study and low airway: 1